Pfizer Announced Positive Topline Results from the Phase 3 HER2CLIMB-05 trial

Pfizer

OncoDaily Party Berlin 2025

ESMO 2025

From Becoming an Expert to Making Experts - CancerWorld

Giuseppe Curigliano

Alexandra La Guardia։ UICC and Fujifilm Europe Present “United by Unique” Exhibition in Geneva

Alexandra La Guardia։ UICC and Fujifilm Europe Present “United by Unique” Exhibition in Geneva

Where to study to become an ESMO President: 2025 Top Institutional Rankings

Where to study to become an ESMO President: 2025 Top Institutional Rankings

Vikas Gupta: New Data From the ENAVEN-AML Trial

Vikas Gupta: New Data From the ENAVEN-AML Trial

100 Influential People in Oncology 2025 - Nominations are Open!

100 Influential People in Oncology 2025

Day 2 Highlights from ASCO Quality Care Symposium 2025

ASCO Quality Care Symposium 2025

OncoCalendar

« All Events

HER2 Positive Breast Cancer: Pathological and Molecular Perspectives

Oct 28 • 6:00 PM - 7:00 PM
Breast Cancer

This webinar provides an in-depth exploration of HER2-positive breast cancer, covering both the pathological and molecular dimensions of the disease. Attendees will gain expert perspectives on the latest developments in tumour biology, molecular profiling, and diagnostic techniques, as well as their influence on clinical decision-making and patient management. The session aims to deliver a clear and current understanding of HER2-positive breast cancer, emphasizing how advances in research and pathology contribute to more personalized treatment strategies.

  • 18:00-18:05 | Welcome and introduction – Aleksandra Filipovic, UK
  • 18:05-18:25 | HER2 positive breast cancer. The pathological perspective – Esther Sanfeliu, ES
  • 18:25-18:45 | HER2 positive breast cancer. Molecular perspective – Mattia Rediti, IT
  • 18:45-18:55 | Discussion and Q&A
  • 18:55-19:00 | Closure – Aleksandra Filipovic, UK

HER2 Positive Breast Cancer: Pathological and Molecular Perspectives

Funded by the European Union – Horizon Europe Grant Agreement No. 101136953.

Views and opinions expressed are however, those of the author(s) only and do not necessarily reflect those of the European Union or HADEA. Neither the European Union nor the granting authority can be held responsible for them.

This work has also received funding from the Swiss State Secretariat for Education, Research and Innovation (SERI).

HER2 Positive Breast Cancer: Pathological and Molecular Perspectives

You can find more posts featuring SPCC on OncoDaily.

Details

Date:
Oct 28
Time:
6:00 PM - 7:00 PM
Website:
https://www.oncocorner.net/index.php?p=events&id=A-516

Organizer

Sharing Progress in Cancer Care
Phone
+41 91 820 09 68
Email
info@spcc.net
View Organizer Website